Tumor Treating Fields (TTFields) are low-intensity wave-like electric fields, tuned to interfere with the division process of cancer cells [Science of TTFields].

TTFields are delivered to the region of the tumor using the Optune® medical device. The Optune System is a portable, light-weight, battery operated device designed to deliver TTFields to glioblastoma (GBM) tumors.

Patients receiving TTFields need to wear four adhesive patches called “transducer arrays” on their scalp, which deliver the fields non-invasively to the location of the GBM tumor. The system is intended for continuous use by patients [Living with TTFields].

TTFields have been approved by the FDA for treatment of adult patients with recurrent and newly diagnosed GBM. What makes the TRIDENT study different is that is testing the use of Optune together with  radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed patients.[The TRIDENT TRIAL].